Physician profile
William Micka
NPI 1376689729
$15,124.50
in general payments reported to CMS, 2019-2025
33 companies · $2,726 in 2025
The $2,726 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,489 · 2020: $983 · 2021: $1,689 · 2022: $2,563 · 2023: $2,722 · 2024: $2,953 · 2025: $2,726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,331 · Consulting Fee: $41.91 · Education: $28.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,330.58 |
| Consulting Fee | $41.91 |
| Education | $28.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $4,264.40 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $1,509.63 | 2019-2025 | Nucala |
| Csl Behring | $1,459.22 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $1,180.66 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Genzyme Corporation | $946.13 | 2019-2025 | |
| Genentech USA, INC. | $777.14 | 2019-2025 | Xolair |
| Amgen INC. | $602.76 | 2021-2025 | Tezspire |
| Pfizer INC. | $588.09 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $540.61 | 2019-2025 | |
| Grifols USA, LLC | $513.32 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $431.98 | 2019-2025 | Dupixent |
| Blueprint Medicines Corporation | $316.61 | 2021-2025 | Ayvakit |
| Biocryst US Sales Co., LLC | $258.73 | 2021-2024 | Orladeyo |
| Pharming Healthcare, INC. | $256.55 | 2019-2025 | Ruconest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.26 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $208.93 | 2019-2023 | Actimmune |
| Kaleo, INC. | $199.03 | 2019-2022 | |
| Alk-Abello, INC | $126.23 | 2020-2023 | Odactra, Ragwitek, Grastek |
| Abbvie INC. | $97.23 | 2023-2024 | |
| Lilly USA, LLC | $89.05 | 2024-2025 | Ebglyss, Taltz |
| Ars Pharmaceuticals Operations, INC. | $69.99 | 2025 | Neffy |
| Hospira, INC. | $61.04 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $54.97 | 2019-2022 | |
| Octapharma USA, INC. | $54.49 | 2023-2024 | Panzyga, Octagam Immune Globulin (Human) |
| Optinose US, INC. | $51.38 | 2021-2022 | |
| Adma Biomanufacturing LLC | $41.91 | 2025 | |
| Tersera Therapeutics LLC | $38.51 | 2025 | Quzyttir |
| Merck Sharp & Dohme LLC | $32.09 | 2023 | |
| Shire North American Group INC | $24.91 | 2019 | |
| Ionis Pharmaceuticals, INC. | $21.99 | 2025 | Dawnzera |
| Hikma Pharmaceuticals USA | $19.19 | 2024 | Ryaltris |
| Biocryst Pharmaceuticals, INC. | $17.03 | 2020 | |
| Incyte Corporation | $14.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Micka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.